These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37476372)

  • 21. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
    Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C
    J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiotherapy Patterns of Care for Locally-advanced Non-small Cell Lung Cancer in the Pre- and Post-durvalumab Era: A Region-wide Survey in a Japanese Prefecture.
    Kubo N; Kobayashi D; Iwanaga M; Matsuura M; Higuchi K; Eishima J; Muramatsu H; Okano N; Shioya M; Onishi M; Aoki T; Oike T; Ohno T;
    J Radiat Res; 2022 Mar; 63(2):264-271. PubMed ID: 34970980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
    Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
    Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice.
    Yamamoto T; Tsukita Y; Katagiri Y; Matsushita H; Umezawa R; Ishikawa Y; Takahashi N; Suzuki Y; Takeda K; Miyauchi E; Saito R; Katsuta Y; Kadoya N; Jingu K
    BMC Cancer; 2022 Apr; 22(1):364. PubMed ID: 35379201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
    Aredo JV; Mambetsariev I; Hellyer JA; Amini A; Neal JW; Padda SK; McCoach CE; Riess JW; Cabebe EC; Naidoo J; Abuali T; Salgia R; Loo BW; Diehn M; Han SS; Wakelee HA
    J Thorac Oncol; 2021 Jun; 16(6):1030-1041. PubMed ID: 33588109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC.
    Hussain S; Klugarova J; Klugar M
    Lung Cancer; 2022 Aug; 170():11-19. PubMed ID: 35691134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
    Senan S; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Murakami S; Hui R; Faivre-Finn C; Paz-Ares L; Wu YL; Mann H; Dennis PA; Antonia SJ
    ESMO Open; 2022 Apr; 7(2):100410. PubMed ID: 35247871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy - single institute experience.
    Vrankar M; Stanic K; Jelercic S; Ciric E; Vodusek AL; But-Hadzic J
    Radiol Oncol; 2021 Nov; 55(4):482-490. PubMed ID: 34821136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).
    Tanzawa S; Makiguchi T; Tasaka S; Inaba M; Ochiai R; Nakamura J; Inoue K; Kishikawa T; Nakashima M; Fujiwara K; Kohyama T; Ishida H; Kuyama S; Miyazawa N; Nakamura T; Miyawaki H; Oda N; Ishikawa N; Morinaga R; Kusaka K; Miyamoto Y; Yokoyama T; Matsumoto C; Tsuda T; Ushijima S; Shibata K; Shibayama T; Bessho A; Kaira K; Misumi T; Shiraishi K; Matsutani N; Seki N
    Ther Adv Med Oncol; 2022; 14():17588359221116603. PubMed ID: 35923924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer.
    Daido W; Masuda T; Imano N; Matsumoto N; Hamai K; Iwamoto Y; Takayama Y; Ueno S; Sumii M; Shoda H; Ishikawa N; Yamasaki M; Nishimura Y; Kawase S; Shiota N; Awaya Y; Suzuki T; Kitaguchi S; Fujitaka K; Nagata Y; Hattori N
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON).
    Saito G; Oya Y; Taniguchi Y; Kawachi H; Daichi F; Matsumoto H; Iwasawa S; Suzuki H; Niitsu T; Miyauchi E; Yokoi T; Yokoyama T; Uenami T; Sakata Y; Arai D; Okada A; Nagata K; Teraoka S; Kokubo M
    Lung Cancer; 2021 Nov; 161():86-93. PubMed ID: 34543942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis.
    Wang Y; Zhang T; Huang Y; Li W; Zhao J; Yang Y; Li C; Wang L; Bi N
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1154-1164. PubMed ID: 34963558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
    Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
    Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone.
    Abe T; Saito S; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
    Thorac Cancer; 2021 Jan; 12(2):245-250. PubMed ID: 33289347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
    Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
    Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
    Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the Efficacy and Toxicity of Concurrent Chemoradiotherapy and Durvalumab and Concurrent Chemoradiotherapy Alone for Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Metastasis.
    Abe T; Iino M; Saito S; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki YU; Miura YU; Kaira K; Kagamu H; Noda SE; Kato S
    Anticancer Res; 2023 Feb; 43(2):675-682. PubMed ID: 36697072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.
    Han J; Tian K; Yang J; Gong Y
    Lung Cancer; 2020 Aug; 146():42-49. PubMed ID: 32512272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC.
    Kuge T; Shiroyama T; Tamiya A; Tamiya M; Kanazu M; Kinehara Y; Tanaka T; Morimura O; Taniguchi Y; Niki T; Tetsumoto S; Hayashi K; Nishino K; Nagatomo I; Kumanogoh A
    JTO Clin Res Rep; 2023 May; 4(5):100505. PubMed ID: 37284296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.